The urgent need to recover MHC class I in cancers for effective immunotherapy
MetadataShow full item record
AuthorGarrido Torres-Puchol, Federico; Aptsiauri, Natalia; Doorduijn, Elien M.; García Lora, Ángel Miguel; van Hall, Thorbald
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Lora, A. M. G., & van Hall, T. (2016). The urgent need to recover MHC class I in cancers for effective immunotherapy. Current opinion in immunology, 39, 44-51. [http://dx.doi.org/10.1016/j.coi.2015.12.007]
SponsorshipFEDER funds (EU) from the Instituto de Salud Carlos III CP03/0111 PI12/02031 PI 08/1265 PI 11/01022 PI11/01386 PI14/01978 PI15/00528 RETIC RD 06/020 RD09/0076/00165 PT13/0010/0039; Junta de Andalucía CTS-143 CTS-695 CTS-3952 CVI-4740 PI 09/0382; Worldwide Cancer Research 15-1166; KWF Kankerbestrijding UL 2010-4785
Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/‘soft’ or irreversible/‘hard’ genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy.